- Home
- SEAT vs TECX Comparison
SEAT vs TECX Comparison
Compare SEAT & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEAT
- TECX
- Stock Information
- Founded
- SEAT 2001
- TECX 2019
- Country
- SEAT United States
- TECX United States
- Employees
- SEAT N/A
- TECX N/A
- Industry
- SEAT Industrial Machinery/Components
- TECX
- Sector
- SEAT Industrials
- TECX
- Exchange
- SEAT Nasdaq
- TECX Nasdaq
- Market Cap
- SEAT 597.1M
- TECX 647.7M
- IPO Year
- SEAT N/A
- TECX 2018
- Fundamental
- Price
- SEAT $4.60
- TECX $48.52
- Analyst Decision
- SEAT Strong Buy
- TECX Strong Buy
- Analyst Count
- SEAT 10
- TECX 5
- Target Price
- SEAT $6.73
- TECX $72.25
- AVG Volume (30 Days)
- SEAT 1.5M
- TECX 97.0K
- Earning Date
- SEAT 11-07-2024
- TECX 02-24-2025
- Dividend Yield
- SEAT N/A
- TECX N/A
- EPS Growth
- SEAT N/A
- TECX N/A
- EPS
- SEAT N/A
- TECX N/A
- Revenue
- SEAT $774,076,000.00
- TECX N/A
- Revenue This Year
- SEAT $10.64
- TECX N/A
- Revenue Next Year
- SEAT $4.21
- TECX N/A
- P/E Ratio
- SEAT $27.06
- TECX N/A
- Revenue Growth
- SEAT 13.91
- TECX N/A
- 52 Week Low
- SEAT $3.24
- TECX $1.40
- 52 Week High
- SEAT $6.41
- TECX $53.41
- Technical
- Relative Strength Index (RSI)
- SEAT 71.67
- TECX 54.40
- Support Level
- SEAT $4.45
- TECX $42.83
- Resistance Level
- SEAT $4.78
- TECX $51.76
- Average True Range (ATR)
- SEAT 0.29
- TECX 3.57
- MACD
- SEAT 0.14
- TECX -0.28
- Stochastic Oscillator
- SEAT 88.08
- TECX 53.87
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease.